Education
About Us
Working with TipRanks
Follow Us
Eyepoint Pharma (EYPT)
:EYPT
EYPT Stock Chart & Stats
$12.11
$0.01(0.11%)
At close: 4:00 PM EST
$12.11
$0.01(0.11%)
Day’s Range― - ―
52-Week Range$3.91 - $14.91
Previous CloseN/A
Volume354.62K
Average Volume (3M)1.32M
Market Cap
$825.75M
Enterprise Value$424.09M
Total Cash (Recent Filing)$255.73M
Total Debt (Recent Filing)$21.82M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Oct 29, 2025EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding68,927,420
10 Day Avg. Volume1,687,443
30 Day Avg. Volume1,324,642
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)1.25
Price to Sales (P/S)9.69
P/FCF Ratio-3.22
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue8.17
Enterprise Value/Gross Profit8.59
Enterprise Value/Ebitda-2.40
Forecast
1Y Price Target
$33.00Price Target Upside172.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe enrollment and randomization of over 400 patients in seven months each for the LUGANO and LUCIA trials demonstrate provider confidence.
Market PositionDuravyu is prepared to launch immediately following a potential approval by the end of 2027, making it the first long-acting TKI to reach market with a differentiated Q6M label.
Regulatory ApprovalEYPT finds itself in the pole position with respect to when the first TKI-based product for wAMD might get approved.
Bears Say
Market RisksRisks include, but are not limited to: failure of DURAVYU in clinical trials, failure to obtain regulatory approval, failure to achieve commercial success due to market size, penetration rate, and/or competition, and potential dilution risk.
Therapeutic EfficacyDeclining rescue-free rates could dent the value proposition of a one-and-done therapy, as patients would anyway need to come in regularly for monitoring, perhaps more frequently with passing time.
EyePoint Pharmaceuticals News
EYPT FAQ
What was Eyepoint Pharma’s price range in the past 12 months?
Eyepoint Pharma lowest stock price was $3.91 and its highest was $14.91 in the past 12 months.
What is Eyepoint Pharma’s market cap?
Eyepoint Pharma’s market cap is $825.75M.
When is Eyepoint Pharma’s upcoming earnings report date?
Eyepoint Pharma’s upcoming earnings report date is Oct 29, 2025 which is today.
How were Eyepoint Pharma’s earnings last quarter?
Currently, no data Available
Is Eyepoint Pharma overvalued?
According to Wall Street analysts Eyepoint Pharma’s price is currently Undervalued.
Does Eyepoint Pharma pay dividends?
Eyepoint Pharma does not currently pay dividends.
What is Eyepoint Pharma’s EPS estimate?
Eyepoint Pharma’s EPS estimate is -0.77.
How many shares outstanding does Eyepoint Pharma have?
Eyepoint Pharma has 68,927,420 shares outstanding.
What happened to Eyepoint Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Eyepoint Pharma?
Currently, no hedge funds are holding shares in EYPT
EyePoint Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (172.50% Upside)
$33.00 (172.50% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 6.2%
Last 30 Days ▲ 6.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.47%
12-Months-Change
Fundamentals
Return on Equity
-73.95%
Trailing 12-Months
Asset Growth
-7.12%
Trailing 12-Months
Company Description
Eyepoint Pharma
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
EYPT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
EyePoint announced significant progress in clinical trials and financial stability, highlighted by the rapid Phase III enrollment for DURAVYU and a strong cash position. However, the company also faced challenges with decreased revenue, increased operating expenses, and a higher net loss. The sentiment of the call reflects optimism about future milestones and the potential market position, but acknowledges the current financial strains due to increased investments in clinical trials.View all EYPT earnings summariesEYPT Stock 12 Month Forecast
Average Price Target
$33.00
▲(172.50% Upside)
Technical Analysis
Urogen Pharma
―
Meiragtx Holdings
―
Stoke Therapeutics
―
Tango Therapeutics
―
Pharming Group
―
Ownership Overview
0.90% Insiders
18.60% Mutual Funds
0.19% Other Institutional Investors
69.89% Public Companies and
Individual Investors